
Synamics Therapeutics is a biotechnology company focused on drug discovery by anticipating disease evolution. Their proprietary platform, Dynaptive™, is designed to predict how diseases will change and develop therapies that stay ahead of these changes. The company aims to transform drug discovery by leveraging evolutionary principles to create innovative medicines.

Synamics Therapeutics is a biotechnology company focused on drug discovery by anticipating disease evolution. Their proprietary platform, Dynaptive™, is designed to predict how diseases will change and develop therapies that stay ahead of these changes. The company aims to transform drug discovery by leveraging evolutionary principles to create innovative medicines.
What they do: AI-driven, evolution-aware drug discovery platform (Dynaptive)
Founded: 2023
Headquarters: California, United States
Team size: ~7 employees
Recent funding: Seed / pre-seed activity, latest round May 9, 2025 (~$4.1M reported)
Drug discovery; mitigating treatment failure and resistance by anticipating disease evolution.
2023
Biotechnology
Reported pre-seed round in July 2024 (Crunchbase/Dealroom record)
$4.1M
Reported May 2025 round with lead investor Plug and Play; Dealroom records ~ $4.1M for May 2025 seed entry
“Plug and Play; Per Falholt; Steen Riisgaard”